Skip to main content

A novel class of antibiotics to combat Antimicrobial Resistance

Project description

Novel peptide-based antibiotics against drug-resistant bacteria

Israel-based Omnix Medical is developing novel antibiotic agents for the treatment of infections caused by drug-resistant bacteria. The company’s proprietary platform technology is changing the biodegradability of antimicrobial peptides, creating a new class of antibiotics with a unique mechanism of action, which is effective regardless of underlying resistance patterns. The goal of the EU-funded OMN6 project is to demonstrate clinical safety and efficacy in the treatment of deadly nosocomial Acinetobacter baumannii infections. To that end, it will support Omnix Medical in the commercialisation of its lead antibiotic candidate, which has already made it past the proof-of-concept stage.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 2 389 674,70
Racah 1
9270401 Jerusalem

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 1 024 146,30